Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease

American Journal of Hematology

Volumn 86, Issue 9, 2011, Pages 806-808

  Mahadeo, Kris M ^a   Oyeku, Suzette ^a   Taragin, Benjamin ^a   Rajpathak, Swapnil N ^a   Moody, Karen ^a   Santizo, Ruth ^a   Catherine Driscoll, M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN F; HYDROXYUREA; LACTATE DEHYDROGENASE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ALPHA THALASSEMIA; BETA THALASSEMIA; BONE RADIOGRAPHY; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; FEMALE; FEMUR HEAD NECROSIS; GENOTYPE; HEMATOCRIT; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETICULOCYTE; RISK ASSESSMENT; SCHOOL CHILD; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; THROMBOCYTE COUNT; VASCULAR DISEASE; VASOOCCLUSIVE CRISIS;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMUR HEAD NECROSIS; GENOTYPE; HUMANS; HYDROXYUREA; NEW YORK; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 80051762413     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22103     Document Type: Letter

References (19)

1. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of Osteonecrosis of the femoral head. N Engl J Med 1991; 325: 1476-1481.
2. Hernigou P, Bachir D, Galacteros F. The natural history of symptomatic osteonecrosis in adult with sickle cell disease. J Bone Joint Surg (Am) 2003; 85A: 500-504.
3. Clarke HJ, Jinnah RH, Brooker AF, Michaelson JD. Total replacement of the hip for avascular necrosis in sickle cell disease. J Bone Joint Surg (Br) 1989; 71: 465-470.
4. Hernigou P, Galacteros F, Bachir D, Goutallier D. Deformities of the hip in adults who have sickle cell disease and had avascular necrosis in childhood. J Bone Joint Surg (Am) 1991; 73: 81-92.
5. Steinberg M, Hayken GD, Steinberg DR. A quantitative system for staging avascular necrosis. J Bone Joint Surg (Br) 1995; 77B: 34-41.
6. Adekile AD, Gupta R, Yacoub F, et al. Avascular necrosis of the hip in children with sickle cell disease and high Hb F: Magnetic resonance imagingfindings and influence of α-thalassemia trait. Acta Haematol 2001; 105: 27-31.
7. Marouf R, Gupta R, Haider MZ, et al. Avascular necrosis of the femoral head in adult Kuwaiti sickle cell diseae patients. Acta Haematol 2003; 110: 11-15.
8. Adekile D, Haider MZ. Morbidity, beta S haplotype and alpha-globin gene patterns among sickle cell anemia patients in Kuwait. Acta Haematol 1996; 96: 150-154.
9. Padmos A, Roberts GT, Sackey K, et al. Two different forms of homozygous sickle cell disease occur in Saudi Arabia. Brit J Haemat 1991; 79: 93-98.
10. Charache S, Terrin M, Moore R, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332: 1317-1322.
11. Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996; 28: 820-828.
12. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996; 88: 1960-1964.
13. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1989; 94: 1550-1554.
14. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood 2005; 2269-2275.
15. De Montalembert M, Brousse V, Elie C, et al. Long-term hydroxyurea treatment in children with sickle cell disease: Tolerance and clinical outcomes. Haematologica 2006; 91: 125-128.
16. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: The Belgian experience. Blood 2005; 105: 2685-2690.
17. Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer 2005; 45: 982-985.
18. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85: 403-408.
19. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17 year, single center trial (LaSHS). Blood 2010; 115: 2354-2363.